Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major cause of morbidity and mortality worldwide, particularly due to the emergence of drug-resistant strains. Membrane-active antimicrobial peptides (AMPs) represent attractive therapeutic candidates because they target bacterial envelope integrity and disrupt essential cellular processes. We evaluated two rationally designed LL-37-derived peptides: a truncated C-terminally amidated analog (LL37-1) and a modified variant incorporating N-terminal acetylation and a single D-amino acid substitution (D-LL37). Dose–response analysis demonstrated that D-LL37 exhibited greater antimycobacterial potency, with lower inhibitory concentrations of 90% (IC90) and 50% (IC50) values (18.40 ± 0.39 μM and 10.11 ± 0.60 μM, respectively) compared with LL37-1 (25.44 ± 0.36 μM and 15.45 ± 1.40 μM). Fluorescence-based permeability assays revealed partial membrane disruption (36% and 44% at IC90 for LL37-1 and D-LL37, respectively), which was supported by ultrastructural alterations observed by scanning electron microscopy, including bacillary shortening, rough surface formation, cell clusters, and the presence of cellular debris, all of which are consistent with membrane damage. RT-qPCR analysis demonstrated significant upregulation of the P-type ATPase genes ctpF, ctpA, and ctpH following D-LL37 exposure. Collectively, these findings indicate that optimized LL-37-derived peptides exert antitubercular activity associated with envelope perturbation and coordinated activation of ion transport-related stress responses.
Background: Klebsiella pneumoniae is one of the leading causes of healthcare-associated neonatal sepsis, with increasing antibiotic resistance and virulence representing major challenges for neonatal care. This study aimed to characterize the molecular epidemiology of K. pneumoniae isolates causing neonatal sepsis at a tertiary referral center in Mexico City and to evaluate the relationship between antibacterial resistance, virulence determinants, clonal dissemination, and neonatal outcomes. Methods: A retrospective observational study was conducted including 57 K. pneumoniae isolates recovered from 39 neonates with culture-confirmed sepsis between 2021 and 2023. Antibiotic susceptibility testing, ESBL production, multidrug resistance, detection of resistance- and virulence-associated genes, multilocus sequence typing, and clinical outcome analyses were performed. Results: A progressive increase in antibiotic resistance and virulence was observed throughout the study period. MDR and ESBL-producing isolates increased from 44.4% and 33.3% in 2021 to 78.9% each in 2023, while isolates with high virulence gene burden increased from 33.3% to 73.7%. The most prevalent resistance genes were blaCTX-M, aac(6′)-Ib, and aac(3)-IIa, whereas uge, ycfM, fimD, and entB were the predominant virulence determinants. High-virulence gene burden was associated with increased prevalence of blaCTX-M and aac(6′)-Ib, while ESBL-producing isolates were associated with ybtS, and MDR isolates were associated with ybtS and uge. PFGE identified a predominant clone (Cluster B) with 100% similarity, characterized by ST45 isolates and significantly higher resistance and virulence profiles. High-virulence isolates were associated with thrombocytopenia and extreme prematurity. Conclusions: K. pneumoniae isolates causing sepsis are increasing antibiotic resistance, virulence gene burden, and clonal dissemination over the three-year study period. The convergence of resistance and virulence determinants highlights the emergence of high-risk hospital-adapted clones and underscores the importance of continuous molecular surveillance to improve infection control and optimize neonatal management.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major cause of morbidity and mortality worldwide, particularly due to the emergence of drug-resistant strains. Membrane-active antimicrobial peptides (AMPs) represent attractive therapeutic candidates because they target bacterial envelope integrity and disrupt essential cellular processes. We evaluated two rationally designed LL-37–derived peptides: a truncated C-terminally amidated analog (LL37-1) and a modified variant incorporating N-terminal acetylation and a single D-amino acid substitution (D-LL37). Dose–response analysis demonstrated that D-LL37 exhibited greater antimycobacterial potency, with lower inhibitory concentrations of 90% (IC90) and 50% (IC50) values (18.40 ± 0.39 μM and 10.11 ± 0.60 μM, respectively) compared with LL37-1 (25.44 ± 0.36 μM and 15.45 ± 1.40 μM). Fluorescence-based permeability assays revealed partial membrane disruption (36% and 44% at IC90 for LL37-1 and D-LL37, respectively), which was supported by ultrastructural alterations observed by scanning electron microscopy, including bacillary shortening, rough surface formation, cell clusters, and the presence of cellular debris, all of which are consistent with membrane damage. RT-qPCR analysis demonstrated significant upregulation of the P-type ATPase genes ctpF, ctpA, and ctpH following D-LL37 exposure. Collectively, these findings indicate that optimized LL-37–derived peptides exert antitubercular activity associated with envelope perturbation and coordinated activation of ion transport-related stress responses.
Background: Syphilis remains a relevant public health problem and continues to be associated with adverse perinatal outcomes. In newborns, conventional serological tests are often difficult to interpret due to maternal antibody transfer and the immaturity of the neonatal immune response. These limitations have led to increasing interest in molecular approaches as complementary diagnostic tools. Methods: This pilot study compared two real-time PCR methodologies for detecting Treponema pallidum DNA in umbilical cord blood: a SYBR Green-based qPCR targeting the polA gene and a TaqMan probe-based qPCR targeting the TpN47 gene. Thirty samples from neonates born to mothers with suspected gestational syphilis were analyzed under standardized conditions. Analytical performance and reproducibility were evaluated before application to clinical samples. Results: Both assays showed stable amplification and acceptable reproducibility. During standardization, the TaqMan assay reached a lower detection limit. However, when applied to clinical samples, the SYBR Green approach identified more positive cases (10/30 vs. 4/30), highlighting differences between analytical performance and behavior in clinical samples. Conclusions: Both methods were suitable for molecular detection of T. pallidum. However, their performance differed in neonatal samples, indicating that analytical sensitivity alone may not predict clinical detection capacity. Molecular testing in cord blood may provide complementary information when serological results are inconclusive.